Free Trial
NASDAQ:PMN

Promis Neurosciences Q3 2025 Earnings Report

Promis Neurosciences logo
$0.45 +0.01 (+2.81%)
Closing price 10/20/2025 04:00 PM Eastern
Extended Trading
$0.44 -0.01 (-3.09%)
As of 08:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Promis Neurosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.15
Beat/Miss
N/A
One Year Ago EPS
N/A

Promis Neurosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Promis Neurosciences Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
6:00PM ET

Conference Call Resources

Promis Neurosciences Earnings Headlines

Gold surges past $4,200 … but this has beat gold by 1,000x
Gold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
See More Promis Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Promis Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Promis Neurosciences and other key companies, straight to your email.

About Promis Neurosciences

Promis Neurosciences (NASDAQ:PMN), Inc. is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation. The company’s pipeline reflects a commitment to addressing unmet needs in neurology by optimizing compound profiles for safety, selectivity and central nervous system penetration.

Promis Neurosciences collaborates with academic institutions and industry partners to accelerate its research and development efforts. These strategic alliances support biomarker identification, translational studies and clinical trial design, aiming to streamline candidate advancement and enrich patient selection strategies.

The company is headquartered in the United States and its common stock trades on the Nasdaq stock exchange under the symbol PMN.

View Promis Neurosciences Profile

More Earnings Resources from MarketBeat